
NASDAQHealthcareBiotechnology
最新数据
US$41.37
−US$2.28 · -5.22%
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
前收盘价
US$41.37
−US$2.28 · -5.22%
盘中时间采用ET。市场数据可能有所延迟。
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
日内区间
当前US$41.37
52周区间
当前US$41.37
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
71
低估
情绪
47
多空交织
风险
44
风险偏高
动量
68
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
日内区间
当前US$41.37
52周区间
当前US$41.37
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 4.51亿 USD | 8.29亿 USD | 355.1万 USD | 2.41亿 USD | 2.43亿 USD |
| 销货成本 | 179.9万 USD | — | 1859.5万 USD | 1249.3万 USD | 1042.1万 USD |
| 毛利 | 4.49亿 USD | 8.29亿 USD | −1504.4万 USD | 2.28亿 USD | 2.33亿 USD |
| 研究与开发 | 7.39亿 USD | 6.07亿 USD | 4.89亿 USD | 3.42亿 USD | 2.89亿 USD |
| 销售、一般及管理费用 | 2.02亿 USD | 1.22亿 USD | 9682万 USD | 9093.2万 USD | 1.24亿 USD |
| 营业费用 | 11.56亿 USD | 7.31亿 USD | 5.86亿 USD | 4.33亿 USD | 4.11亿 USD |
| 利息收入 | 5786.4万 USD | 3728.9万 USD | 2272万 USD | 1529.9万 USD | 503.3万 USD |
| 利息支出 | 9370.8万 USD | 8936.1万 USD | 3235.2万 USD | 1832.6万 USD | — |
| 折旧和摊销 | 2662.2万 USD | 2392.8万 USD | 1859.5万 USD | 1249.3万 USD | 1042.1万 USD |
| 营业利润 | −7.07亿 USD | 9834.6万 USD | −6.01亿 USD | −2.05亿 USD | −1.79亿 USD |
| 净利润 | −7.24亿 USD | −163.1万 USD | −5.99亿 USD | −2.05亿 USD | −1.76亿 USD |
公司数据更新于 2026年11月22日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$111.2
上涨空间 168.79%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2011年11月17日 | 1:10 | — | — |
股票拆分 | 2004年1月15日 | 1:65 | — | — |
已生效 2011年11月17日
1:10
已生效 2004年1月15日
1:65
报告持有此股票敞口的交易所交易基金。
iShares Core S&P Mid-Cap ETFIJH2.11亿0.18%1150.6亿 USD0.05%US$68.60-2.68%
Vanguard Morningstar Total Stock Market ETFVTI2.02亿0.01%6893亿 USD0.03%US$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB1.8亿0.10%787亿 USD0.03%US$270.68-2.56%
Vanguard Morningstar Small-Cap Growth ETFVBK1.01亿0.23%225亿 USD0.05%US$298.35-3.85%
Vanguard Extended Market ETFVXF9599.63万0.10%302亿 USD0.05%US$211.44-3.21%
State Street SPDR S&P Biotech ETFXBI8000.7万0.83%96.36亿 USD0.35%US$140.18-2.73%
Invesco S&P MidCap Momentum ETFXMMO7648.38万1.28%57.15亿 USD0.34%US$123.11-4.15%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY4616.24万0.19%245.19亿 USD0.23%US$626.03-2.64%
iShares Core S&P Mid-Cap ETFIJH
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
State Street SPDR S&P Biotech ETFXBI
Invesco S&P MidCap Momentum ETFXMMO
State Street SPDR S&P MIDCAP 400 ETF TrustMDYAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。